IN8bio Inc. (NASDAQ:INAB) shares received a positive update from Jones Trading as analyst Soumit Roy upgraded the company's stock rating from Hold to Buy. Along with the rating change, Roy established ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

IN8bio (INAB) announced new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100, an allogeneic gamma-delta T cell ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

16, 2024 — Scientists have developed a new blood test that could screen cancer patients to help make their treatment ... mechanism by which acute myeloid leukemia (AML) cells sustain their ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

This valuable study presents a mouse gastruloid model that can be used to generate hematopoietic progenitors as well as leukemic cells. However, in its current form, the manuscript is inadequate ...

The Statesboro community is rallying behind U.S. Army veteran Matthew Kleinsorge, a devoted father of four, as he battles ...

This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

Nelson Aguilar is an LA-based tech how-to writer and graduate of UCLA. With more than a decade of experience, he covers Apple and Google and writes on iPhone and Android features, privacy and ...